Saturday 17 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 17.50 | 4.01 | 4.00 | 2.02 | 3.71 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 87.30 | 23.50 | 28.70 | 18.18 | 11.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 1 | 9 | 12 | 14 | 23 | 22 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.08 | 0.05 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 1 | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 100.00 | 100.00 | — | — | |||||
| EBT | — | — | (1) | (2) | (2) | (10) | (18) | (31) | (37) | (27) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,898.84) | (4,525.04) | 0.00 | 0.00 | |||||
| Net income | — | 0 | (1) | (2) | (2) | (10) | (18) | (31) | (37) | (27) | |||||
| Depreciation | — | — | — | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.63 | 0.28 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.07) | (2.67) | (2.66) | (8.60) | (12.00) | (12.80) | (5.60) | (1.67) | |||||
| Cash flow | — | — | (0.05) | (1.45) | (1.72) | (4.94) | (10.39) | (7.45) | (4.27) | (1.97) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (0.05) | (1.45) | (1.72) | (4.96) | (10.40) | (7.46) | (4.28) | (1.97) | |||||
| Book value | — | — | (0.08) | (1.09) | (3.14) | 14.12 | (0.31) | (1.55) | 1.11 | 1.90 | |||||
| Shares, m | — | — | 15 | 1 | 1 | 1 | 2 | 2 | 7 | 16 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | — | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | (0.46) | (0.66) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (1) | (1) | (6) | (16) | (18) | (29) | (31) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | (1) | (1) | (1) | (6) | (16) | (18) | (29) | (31) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | (1) | (1) | (3) | 16 | (1) | (4) | 7 | 30 | ||||
| Total debt | — | — | 1 | 0 | 1 | 0 | 0 | — | — | — | |||||
| Net debt | — | — | 1 | 0 | 1 | (17) | 0 | (10) | (26) | (41) | |||||
| Shareholders’ equity | — | — | (1) | (1) | (3) | 16 | 0 | (4) | 7 | 30 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (7,724.14) | (9,020.83) | (2,030.49) | (105.73) | (167.50) | (369.35) | (164.96) | (65.73) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 0.00 | 207.18 | 127.37 | (145.04) | (225.47) | 1,469.52 | (2,088.57) | (141.14) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Mar 2023
Charts ten years each
Unicycive Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| COYA Coya Therapeutics, Inc. | $101.8M | — (loss-making) | — (loss-making) | +48.96% (above 0%: growing) | n/m | −27.79% (below 0%: shrinking) | 100.00% | (2,891.67%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | |
| BDTX Black Diamond Therapeutics, Inc. | $100.0M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PYPD PolyPid Ltd. | $99.5M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $98.9M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| CBUS Cibus, Inc. | $98.6M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $97.4M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRXS Neuraxis, Inc. | $97.2M | — (loss-making) | — (loss-making) | +115.71% (above 0%: growing) | n/m | +29.76% (above 0%: growing) | 85.87% | (110.16%) | Compare |
| IMUX Immunic, Inc. | $96.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $98.8M | — | — | +27.75% | — | −6.94% | 90.07% | (55.08%) |
Unicycive Therapeutics, Inc. (UNCY) key facts
- Concern: Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022.
- Unicycive Therapeutics, Inc. (UNCY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, UNCY traded at $3.36, a market capitalization of $100.0 million.
- Return on equity was −141.1% and debt-to-equity 0.00.
- Its Altman Z-score is −10.79 (distress zone) for fiscal 2023.